Nafeeza Hafeez

US Patent:

20060025460, Feb 2, 2006

Filed:

Jun 17, 2005

Appl. No.:

11/156364

Inventors:

Alfredo Castro - Winchester MA, US
Wei Deng - Lexington MA, US
Kristopher Depew - Acton MA, US
Michael Foley - Chestnut Hill MA, US
Christian Fritz - Natick MA, US
Asimina Georges Evangelinos - Andover MA, US
Michael Grogan - Arlington MA, US
Nafeeza Hafeez - West Roxbury MA, US
Edward Holson - Newton Highlands MA, US
Brian Hopkins - Brookline MA, US
Nii Koney - Somerville MA, US
Tao Liu - Ashland MA, US
David Mann - Swampscott MA, US
Lisa Marcaurelle - Arlington MA, US
Daniel Snyder - Cambridge MA, US
Dennis Underwood - Jamaica Plain MA, US
Andrew Wylie - Brookline MA, US
Lin-Chen Yu - Wollaston MA, US
Linping Zhang - Lexington MA, US

Assignee:

Infinity Pharmaceuticals, Inc. - Cambridge MA

International Classification:

C07D 261/02
A61K 31/42

US Classification:

514378000, 548240000

Abstract:

One aspect of the present invention relates to heterocyclic compounds that bind to bcl proteins and inhibit Bcl function. Another aspect of the present invention relates to compositions comprising a heterocyclic compound of the invention. The present invention provides methods for treating and modulating disorders associated with hyperproliferation, such as cancer.

US Patent:

20180064709, Mar 8, 2018

Filed:

Mar 23, 2016

Appl. No.:

15/561209

Inventors:

Nicole Buschmann - Basel, CH
Robin Alec Fairhurst - Basel, CH
Jorge Garcia Fortanet - Wilmington MA, US
Pascal Furet - Thann, FR
Diana Graus Porta - Basel, CH
Nafeeza Hafeez - Brookline MA, US
Bo Han - Shanghai, CN
Thomas Knoepfel - Rheinfelden, CH
Matthew J. LaMarche - Reading MA, US
Catherine Leblanc - Basel, CH

International Classification:

A61K 31/496
A61K 31/497

Abstract:

A pharmaceutical combination comprising N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide, or a pharmaceutically acceptable salt thereof, and at least one active ingredient, as defined herein, or a pharmaceutically acceptable salt thereof, and optionally a pharmaceutically acceptable carrier, for simultaneous or sequential administration; the uses of such combination in the treatment of proliferative diseases; and methods of treating a subject suffering from a proliferative disease comprising administering a therapeutically effective amount of such combination.

US Patent:

20170304313, Oct 26, 2017

Filed:

Oct 2, 2015

Appl. No.:

15/517035

Inventors:

- Basel, CH
Nafeeza Hafeez - Cambridge MA, US

International Classification:

A61K 31/55
A61K 31/496
A61K 31/506
A61K 45/06

Abstract:

This invention relates to a pharmaceutical combination comprising (a) an EGFR inhibitor and (b) a FGFR inhibitor, particularly for use in the treatment of a cancer. This invention also relates to uses of such combination for preparation of a medicament for the treatment of a cancer; methods of treating or preventing a cancer in a subject in need thereof comprising administering to said subject a jointly therapeutically effective amount of said combination; pharmaceutical compositions comprising such combination and commercial packages thereto.